Literature DB >> 19224197

A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans.

A Kotronen1, L E Johansson, L M Johansson, C Roos, J Westerbacka, A Hamsten, R Bergholm, P Arkkila, J Arola, T Kiviluoto, R M Fisher, E Ehrenborg, M Orho-Melander, M Ridderstråle, L Groop, H Yki-Järvinen.   

Abstract

AIMS/HYPOTHESIS: It has recently been suggested that the rs738409 G allele in PNPLA3, which encodes adiponutrin, is strongly associated with increased liver fat content in three different ethnic groups. The aims of the present study were as follows: (1) to try to replicate these findings in European individuals with quantitative measures of hepatic fat content; (2) to study whether the polymorphism influences hepatic and adipose tissue insulin sensitivity; and (3) to investigate whether PNPLA3 expression is altered in the human fatty liver.
METHODS: We genotyped 291 Finnish individuals in whom liver fat had been measured using proton magnetic resonance spectroscopy. Hepatic PNPLA3 expression was measured in 32 participants. Hepatic and adipose tissue insulin sensitivities were measured using a euglycaemic-hyperinsulinaemic (insulin infusion 0.3 mU kg(-1) min(-1)) clamp technique combined with infusion of [3-(3)H]glucose in 109 participants.
RESULTS: The rs738409 G allele in PNPLA3 was associated with increased quantitative measures of liver fat content (p = 0.011) and serum aspartate aminotransferase concentrations (p = 0.002) independently of age, sex and BMI. Fasting serum insulin and hepatic and adipose tissue insulin sensitivity were related to liver fat content independently of genotype status. PNPLA3 mRNA expression in the liver was positively related to obesity (r = 0.62, p < 0.0001) and to liver fat content (r = 0.58, p = 0.025) in participants who were not morbidly obese (BMI < 40 kg/m(2)). CONCLUSIONS/
INTERPRETATION: A common variant in PNPLA3 increases the risk of hepatic steatosis in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224197     DOI: 10.1007/s00125-009-1285-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  13 in total

1.  Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.

Authors:  Lidia S Szczepaniak; Pamela Nurenberg; David Leonard; Jeffrey D Browning; Jason S Reingold; Scott Grundy; Helen H Hobbs; Robert L Dobbins
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-08-31       Impact factor: 4.310

2.  Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members.

Authors:  Andrew C Lake; Ying Sun; Jian-Liang Li; Jae Eun Kim; Jeremy W Johnson; Dongmei Li; Tracy Revett; Heather H Shih; Wei Liu; Janet E Paulsen; Ruth E Gimeno
Journal:  J Lipid Res       Date:  2005-09-08       Impact factor: 5.922

3.  Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage.

Authors:  S Baulande; F Lasnier; M Lucas; J Pairault
Journal:  J Biol Chem       Date:  2001-06-28       Impact factor: 5.157

4.  Variation in the adiponutrin gene influences its expression and associates with obesity.

Authors:  Lovisa E Johansson; Johan Hoffstedt; Hemang Parikh; Emma Carlsson; Martin Wabitsch; Anne-Greth Bondeson; Jan Hedenbro; Hans Tornqvist; Leif Groop; Martin Ridderstråle
Journal:  Diabetes       Date:  2006-03       Impact factor: 9.461

Review 5.  Nonalcoholic fatty liver disease: a review of current understanding and future impact.

Authors:  Michael Charlton
Journal:  Clin Gastroenterol Hepatol       Date:  2004-12       Impact factor: 11.382

6.  Effect of liver fat on insulin clearance.

Authors:  Anna Kotronen; Satu Vehkavaara; Anneli Seppälä-Lindroos; Robert Bergholm; Hannele Yki-Järvinen
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-09-25       Impact factor: 4.310

7.  Liver fat in the metabolic syndrome.

Authors:  Anna Kotronen; Jukka Westerbacka; Robert Bergholm; Kirsi H Pietiläinen; Hannele Yki-Järvinen
Journal:  J Clin Endocrinol Metab       Date:  2007-06-26       Impact factor: 5.958

8.  Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes.

Authors:  Anna Kotronen; Leena Juurinen; Mirja Tiikkainen; Satu Vehkavaara; Hannele Yki-Järvinen
Journal:  Gastroenterology       Date:  2008-03-21       Impact factor: 22.682

9.  Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities.

Authors:  Christopher M Jenkins; David J Mancuso; Wei Yan; Harold F Sims; Beverly Gibson; Richard W Gross
Journal:  J Biol Chem       Date:  2004-09-10       Impact factor: 5.157

10.  Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.

Authors:  Xin Yuan; Dawn Waterworth; John R B Perry; Noha Lim; Kijoung Song; John C Chambers; Weihua Zhang; Peter Vollenweider; Heide Stirnadel; Toby Johnson; Sven Bergmann; Noam D Beckmann; Yun Li; Luigi Ferrucci; David Melzer; Dena Hernandez; Andrew Singleton; James Scott; Paul Elliott; Gerard Waeber; Lon Cardon; Timothy M Frayling; Jaspal S Kooner; Vincent Mooser
Journal:  Am J Hum Genet       Date:  2008-10       Impact factor: 11.025

View more
  106 in total

1.  Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD.

Authors:  Samer Gawrieh; Miranda C Marion; Richard Komorowski; James Wallace; Michael Charlton; Ahmed Kissebah; Carl D Langefeld; Michael Olivier
Journal:  Dig Dis Sci       Date:  2011-12-09       Impact factor: 3.199

2.  Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease.

Authors:  Weiqin Chen; Benny Chang; Lan Li; Lawrence Chan
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

3.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.

Authors:  Elizabeth K Speliotes; Johannah L Butler; Cameron D Palmer; Benjamin F Voight; Joel N Hirschhorn
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

4.  Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study.

Authors:  Lynne E Wagenknecht; Nicholette D Palmer; Donald W Bowden; Jerome I Rotter; Jill M Norris; Julie Ziegler; Yii-Der I Chen; Steven Haffner; Ann Scherzinger; Carl D Langefeld
Journal:  Liver Int       Date:  2011-01-13       Impact factor: 5.828

5.  Inherited susceptibility to non-alcoholic fatty liver disease.

Authors:  R J F Loos; D B Savage
Journal:  Diabetologia       Date:  2009-03-25       Impact factor: 10.122

6.  Variant in PNPLA3 is associated with alcoholic liver disease.

Authors:  Chao Tian; Renee P Stokowski; David Kershenobich; Dennis G Ballinger; David A Hinds
Journal:  Nat Genet       Date:  2009-11-29       Impact factor: 38.330

7.  Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population.

Authors:  Elena Larrieta-Carrasco; Yvonne N Flores; Luis R Macías-Kauffer; Paula Ramírez-Palacios; Manuel Quiterio; Eric G Ramírez-Salazar; Paola León-Mimila; Berenice Rivera-Paredez; Guillermo Cabrera-Álvarez; Samuel Canizales-Quinteros; Zuo-Feng Zhang; Tania V López-Pérez; Jorge Salmerón; Rafael Velázquez-Cruz
Journal:  Exp Mol Pathol       Date:  2018-01-04       Impact factor: 3.362

8.  Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea.

Authors:  Sang Soo Lee; Young-Sang Byoun; Sook-Hyang Jeong; Byung Hyun Woo; Eun Sun Jang; Jin-Wook Kim; Hyun Young Kim
Journal:  Dig Dis Sci       Date:  2014-07-29       Impact factor: 3.199

9.  Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.

Authors:  Panu K Luukkonen; Taru Tukiainen; Anne Juuti; Henna Sammalkorpi; P A Nidhina Haridas; Onni Niemelä; Johanna Arola; Marju Orho-Melander; Antti Hakkarainen; Petri T Kovanen; Om Dwivedi; Leif Groop; Leanne Hodson; Amalia Gastaldelli; Tuulia Hyötyläinen; Matej Orešič; Hannele Yki-Järvinen
Journal:  JCI Insight       Date:  2020-03-12

Review 10.  PNPLA3 genetic variation in alcoholic steatosis and liver disease progression.

Authors:  Felix Stickel; Jochen Hampe; Eric Trépo; Christian Datz; Stefano Romeo
Journal:  Hepatobiliary Surg Nutr       Date:  2015-06       Impact factor: 7.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.